AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01069523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
Study NCT03840083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Participants will sleep (either a mid-day nap or normal overnight sleep)
Study NCT01449201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: 45 mg P.O. Daily (28-day treatment as one treatment cycle)
Study NCT03217773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Refer to arm description
Study NCT03217773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAMIS
Description: Refer to arm description
Study NCT03523221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
Study NCT03523221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Oral
Description: use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
Study NCT01674244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Exercise
Study NCT01674244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor Only Waitlist
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pradigastat Tablets 40mg matching Placebo
Description: once daily, oral administration
Study NCT01112358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analogous GnRH antagonist
Description: Analogous GnRH antagonist will be administered as specified in the arm description.
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 40mg matching Placebo
Description: once daily, oral administration
Study NCT02297412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Given PO
Study NCT02297412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02297412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02297412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02297412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02297412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02479191 — intervention group
Intervention type: DEVICE
Intervention: Ovation Abdominal Stent Graft Platform
Study NCT04700150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi 2 month
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study NCT04700150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi 4 month
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study NCT01112358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hCG
Description: r-hCG will be administered as specified in the arm description.
Study NCT01112358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG will be administered as specified in the arm description.
Study NCT01112358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone will be administered as specified in the arm description.
Study NCT01112358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone will be administered as specified in the arm description.
Study NCT01099137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg twice a day, orally, for 24 weeks
Study NCT01099137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylurea dose-up
Description: glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
Study NCT03825757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT03825757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: Primaspan 250 mg tablet Acetyl Salicylic Acid
Study NCT03081689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg
Description: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
Study NCT03081689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200mg/m2
Description: Paclitaxel 200mg/m2 IV Q3W
Study NCT03081689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC 6 IV Q3W
Study NCT03594396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg bid will be given on days 1-28 days without rest.
Study NCT03594396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
Study NCT03564236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Therapy
Description: Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
Study NCT03564236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard regular care of a COPD exacerbation
Study NCT03069716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Text Messaging
Description: A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
Study NCT03069716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit Charge HR
Description: The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
Study NCT03069716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR
Description: The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
Study NCT03416725 — intervention group
Intervention type: DEVICE
Intervention: Otoscope
Description: Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
Study NCT00000409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laminectomy
Description: Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
Study NCT00000409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
Study NCT00000409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion--Instrumented
Description: In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
Study NCT00000409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion-Non-instrumented
Description: additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
Study NCT00667407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Description: levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days
Study NCT00667407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol Sulfate
Description: Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days
Study NCT03538548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RP
Description: CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
Study NCT03994107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6.
Study NCT03994107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
Study NCT03994107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
Study NCT01272674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: 4 weeks supervised physical exercise training
Study NCT02782728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS-Plus
Description: Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
Study NCT03694808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD Vaccine
Description: single high dose (HD) intramuscular injection
Study NCT00002787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immunoglobulin idiotype-KLH conjugate vaccine
Description: Given SC
Study NCT02782728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIPS-Basic
Description: Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
Study NCT02966431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Study NCT02966431 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Counseling
Study NCT00440583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy followed by Zevalin
Description: 6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
Study NCT03954197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No hormone
Description: No hormonal injection before oocytes retrieval
Study NCT03954197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
Study NCT03480854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
Study NCT04303156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Single oral dose of 60 mg Islatravir administered in capsule form
Study NCT02570568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinlite
Description: Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
Study NCT02570568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen-torch Transillumination
Description: Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
Study NCT02570568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Venepuncture
Description: This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
Study NCT01077934 — intervention group
Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
Study NCT03705442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omni-Biotic 10
Description: All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
Study NCT03705442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: loperamide (Seldiar)
Description: All the patients will have access to standard drugs for diarrhoea
Study NCT03705442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide (Seldiar)
Description: All the patients will have access to standard drugs for diarrhoea
Study NCT04291729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganovo+ritonavir+/-Interferon nebulization
Description: Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
Study NCT03352778 — intervention group
Intervention type: RADIATION
Intervention: IMRT
Description: 66Gy by intensity-modulated radiotherapy
Study NCT03352778 — intervention group
Intervention type: RADIATION
Intervention: 2DRT
Description: 66Gy by 2-dimensional radiotherapy
Study NCT02889718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONCERT-CL® station
Description: During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare
Study NCT02889718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
Study NCT04395235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
Study NCT00002787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00002787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00002787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02315066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
Study NCT02315066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
Study NCT02315066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600 plus PF-05082566
Description: Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
Study NCT02315066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600 plus PF-05082566
Description: Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
Study NCT03099629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
Study NCT01232491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.